Dare Bioscience, Inc. (DARE) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Dare Bioscience, Inc. is a women's health biotech company operating in a single segment. The company has shifted its strategy to a "dual-path" approach, pursuing both traditional FDA approval and earlier market access via Section 503B compounding for select products. Key pipeline assets include Ovaprene (Phase 3), DARE-HPV (Phase 2), and DARE to PLAY (Section 503B).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $152,455 | $25,427 |
| Net Loss | $(2,999,889) | $(4,378,307) |
| Loss Per Share (Basic & Diluted) | $(0.21) | $(0.50) |
| Operating Expenses | $2,909,028 | $4,606,545 |
| Cash and Cash Equivalents (End of Period) | $18,519,784 | $10,329,967 |
| Working Capital | ~$0.5 million | N/A |
| Accumulated Deficit | $(191.7 million) | $(179.7 million) |
Liquidity Note: A significant portion of the reported cash ($18.5 million) is restricted by grant agreements. The company holds a deferred grant funding liability of approximately $18.2 million, representing funds received but not yet expended on direct costs.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased 500% to $152,455, driven by new research and development services agreements with the Gates Foundation. This partially offset a decrease in non-cash royalty revenue from XACIATO.
- Expense Reduction: Total operating expenses decreased 37% to $2.9 million. Research and Development (R&D) expenses dropped 71% to $660,462, primarily due to increased "contra R&D expenses" (grant funding offsets) totaling $3.5 million in Q1 2026 compared to $3.1 million in Q1 2025.
- Net Loss Improvement: Net loss narrowed by 31% to $3.0 million, reflecting the reduction in R&D expenses.
- Financing Activity: The company raised approximately $0.3 million in net proceeds from the issuance of Series A Convertible Preferred Stock and warrants under its Regulation A offering and $0.1 million from an equity line with Lincoln Park Capital.
Guidance, Outlook, and Risks
- Going Concern: The company has expressed substantial doubt about its ability to continue as a going concern for the 12 months following the report date due to recurring losses, negative cash flows, and the uncertainty of future revenue from commercialization efforts.
- Capital Needs: Dare Bioscience requires additional capital to fund operations and development. It is actively pursuing its Regulation A offering (up to $24.3 million potential gross proceeds) and other financing options.
- Commercialization Timeline: The company expects to begin recording revenue from DARE to PLAY sales in Q3 2026 and from Flora Sync LF5 (DARE to RESTORE) in June 2026, though revenue amounts remain uncertain.
- Regulatory & Listing Risks:
- Nasdaq Compliance: The company was not in compliance with the Nasdaq Stockholders' Equity Rule ($2.5 million) as of March 31, 2026. It is subject to a mandatory monitoring period and risks delisting if it cannot meet equity or market value requirements.
- Grant Funding: Recent federal government actions have caused administrative backlogs at the NIH, delaying drawdowns on existing awards, though legislative reauthorization of SBIR/STTR programs occurred in April 2026.
- Product Updates:
- Ovaprene: Phase 3 enrollment is ongoing; interim data showed a 9% pregnancy rate and no new safety concerns.
- DARE-HPV: Received FDA clearance for a Phase 2 study in February 2026.
Investor Verification Checklist
- Grant Fund Utilization: Verify the specific restrictions on the $18.2 million deferred grant liability and the timeline for recognizing these funds as revenue offsets versus cash burn.
- Nasdaq Compliance Status: Monitor the company's progress in regaining compliance with Nasdaq listing standards (Stockholders' Equity or Market Value of Listed Securities) to avoid delisting.
- Regulation A Offering Progress: Track the pace of the Regulation A offering and the conversion of Series A Preferred Stock to assess dilution and capital runway.
- Commercialization Execution: Confirm the actual launch dates and initial sales volumes for DARE to PLAY and DARE to RESTORE, as these are critical to the company's path to profitability.
- Grant Funding Continuity: Assess the impact of federal administrative backlogs on the timing of future grant disbursements for DARE-HPV and Ovaprene.